TY - JOUR
T1 - Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma
T2 - A cooperation task force (CTF) study
AU - Gadducci, Angiolo
AU - Cosio, Stefania
AU - Landoni, Fabio
AU - Maggino, Tiziano
AU - Zola, Paolo
AU - Fuso, Luca
AU - Sartori, Enrico
PY - 2012
Y1 - 2012
N2 - Objective: To assess the pattern of failures and the survival of patients with uterine papillary serous carcinoma (UPSC). Methods: The hospital records of 119 women with UPSC were reviewed. Surgery was the initial therapy for all the cases. The median follow-up of survivors was 133 months (range, 3Y216 months). Results: Postoperative treatment was used in 98 patients (82.4%). Adjuvant treatment was radiotherapy in 25 women, chemotherapy in 61 women, and chemotherapy plus radiotherapy in 12 women. Tumor recurred in 44 (37.0%) of the 119 patients, after a median time of 15.1 months. Relapse was symptomatic in 15 patients (34.1%), and recurrent disease involved peritoneum or distant sites in 26 (66.7%) of the 39 patients for whom the site of failure was known. Five- and 10-year survival rates were 61.8% and 54.6%, respectively. Survival was related to disease stage (P G 0.0001). Among patients with advanced tumor, 5-year survival was lower in women who had macroscopic residual disease after surgery than in those who had not (15.4% vs 37.5%; P = 0.08). Distant failures were higher in women with histologically proven positive nodes than in those with negative nodes (28.6% vs 9.1%; P = 0.048). There was a trend to better survival for patients with stage I to stage II disease who underwent chemotherapy when compared with those who did not. Conclusions: Uterine papillary serous carcinoma has an aggressive clinical behavior with a great tendency to recur especially in peritoneal and distant sites. Tumor stage is a strong prognostic factor, whereas the role of adjuvant treatment is still uncertain.
AB - Objective: To assess the pattern of failures and the survival of patients with uterine papillary serous carcinoma (UPSC). Methods: The hospital records of 119 women with UPSC were reviewed. Surgery was the initial therapy for all the cases. The median follow-up of survivors was 133 months (range, 3Y216 months). Results: Postoperative treatment was used in 98 patients (82.4%). Adjuvant treatment was radiotherapy in 25 women, chemotherapy in 61 women, and chemotherapy plus radiotherapy in 12 women. Tumor recurred in 44 (37.0%) of the 119 patients, after a median time of 15.1 months. Relapse was symptomatic in 15 patients (34.1%), and recurrent disease involved peritoneum or distant sites in 26 (66.7%) of the 39 patients for whom the site of failure was known. Five- and 10-year survival rates were 61.8% and 54.6%, respectively. Survival was related to disease stage (P G 0.0001). Among patients with advanced tumor, 5-year survival was lower in women who had macroscopic residual disease after surgery than in those who had not (15.4% vs 37.5%; P = 0.08). Distant failures were higher in women with histologically proven positive nodes than in those with negative nodes (28.6% vs 9.1%; P = 0.048). There was a trend to better survival for patients with stage I to stage II disease who underwent chemotherapy when compared with those who did not. Conclusions: Uterine papillary serous carcinoma has an aggressive clinical behavior with a great tendency to recur especially in peritoneal and distant sites. Tumor stage is a strong prognostic factor, whereas the role of adjuvant treatment is still uncertain.
KW - Chemotherapy
KW - Pattern of failure
KW - Radiotherapy
KW - Surgical staging
KW - Uterine papillary serous carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84867281303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867281303&partnerID=8YFLogxK
U2 - 10.1097/IGC.0b013e318267f7a0
DO - 10.1097/IGC.0b013e318267f7a0
M3 - Article
C2 - 22976496
AN - SCOPUS:84867281303
VL - 22
SP - 1355
EP - 1360
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 8
ER -